Adequan i.m.This page contains information on Adequan i.m. for veterinary use.
The information provided typically includes the following:
- Adequan i.m. Indications
- Warnings and cautions for Adequan i.m.
- Direction and dosage information for Adequan i.m.
Adequan I.m.This treatment applies to the following species:
Brand of Polysulfated Glycosaminoglycan (PSGAG)
Solution 500 mg/5 mL
For Intramuscular Use In Horses
Adequan i.m. CautionFederal law restricts this drug to use by or on the order of a licensed veterinarian.
DescriptionEach 5 milliliters of Adequan® i.m. contains 500 mg of Polysulfated Glycosaminoglycan and Water for Injection q.s. Sodium Hydroxide and/or Hydrochloric Acid added when necessary to adjust pH. Sodium Chloride may be added to adjust tonicity.
PharmacologyPolysulfated Glycosaminoglycan is chemically similar to the glycosaminoglycans in articular cartilage matrix. PSGAG is a potent proteolytic enzyme inhibitor and diminishes or reverses the pathologic processes of traumatic or degenerative joint disease which result in a net loss of cartilage matrix components. PSGAG improves joint function by reducing synovial fluid protein levels and increasing synovial fluid hyaluronic acid concentration in traumatized equine carpal and hock joints.
Adequan i.m. IndicationsAdequan® i.m. is recommended for the intramuscular treatment of non-infectious degenerative and/or traumatic joint dysfunction and associated lameness of the carpal and hock joints in horses.
Adequan i.m. Dosage And AdministrationThe recommended dose of Adequan® i.m. in horses is 500 mg every 4 days for 28 days intramuscularly. The injection site must be thoroughly cleansed prior to injection. Do not mix Adequan® i.m. with other drugs or solvents.
ContraindicationsThere are no known contraindications to the use of intramuscular Polysulfated Glycosaminoglycan.
WarningsDo not use in horses intended for human consumption. Not for use in humans. Keep this and all medications out of the reach of children.
PrecautionsThe safe use of Adequan® i.m. in horses used for breeding purposes, during pregnancy, or in lactating mares has not been evaluated.
Animal SafetyToxicity studies were conducted in horses. Doses as high as 2,500 mg were administered intramuscularly to 6 horses twice a week for 12 weeks. This dosage is 5 times the recommended dosage and 3 times the recommended therapeutic regimen. Clinical observations revealed no soreness or swelling at the injection site or in the affected joint. No animal had any clinical or laboratory evidence of toxicity.
Storage ConditionsStore at 20°-25°C (68°-77°F); excursions permitted to 15°-30°C (59°-86°F) (See USP Controlled Room Temperature). Discard unused portion. Dispose of spent needles in accordance with all federal, state and local environmental laws.
How SuppliedAdequan® i.m. solution, 500 mg/5 mL is available in 5 mL glass vials, packaged in boxes of 7.
Store at controlled room temperature up to 25°C (77°F) (See USP). Discard unused portion.
Luitpold Pharmaceuticals, Inc., animal Health Division, Shirley, Ny 11967
Made in U.S.A.
NADA #140-901, Approved by FDA
Animal Health Division
ONE LUITPOLD DRIVE, P.O. BOX 9001, SHIRLEY, NY, 11967
|Every effort has been made to ensure the accuracy of the Adequan i.m. information published above. However, it remains the responsibility of the readers to familiarize themselves with the product information contained on the US product label or package insert.|
Copyright © 2017 North American Compendiums. Updated: 2017-07-10